Mon panier

Biotinylated Human NCAM-1 / CD56 Protein, His,Avitag™ (MALS verified)

Numéro de produit/spécification
Prix
Qté
NC1-H82E3-25ug
$360.00
NC1-H82E3-200ug
$1565.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    CD56, MSK39, NCAM1, N-CAM-1

  • Source

    Biotinylated Human NCAM-1, His,Avitag (NC1-H82E3) is expressed from human 293 cells (HEK293). It contains AA Leu 20 – Gly 718 (Accession # P13591-2).

    Predicted N-terminus: Leu 20

    Request for sequence
  • Molecular Characterization

    NCAM-1 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 81.0 kDa. The protein migrates as 95-115 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Endotoxin

    Less than 0.1 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 500 mM NaCl, pH8.0 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 12 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    NCAM-1 SDS-PAGE

    Biotinylated Human NCAM-1, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • SEC-MALS

    NCAM-1 SEC-MALS

    The purity of Biotinylated Human NCAM-1, His,Avitag (Cat. No. NC1-H82E3) is more than 95% and the molecular weight of this protein is around 95-135 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     NCAM-1 ELISA

    Immobilized Biotinylated Human NCAM-1, His,Avitag (Cat. No. NC1-H82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-NCAM-1 Antibody, Human IgG1 with a linear range of 1-5 ng/mL (QC tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

NCAM1 belongs to the immunoglobulin superfamily of adhesion molecules. A wide range of alternatively spliced NCAM1 messenger RNAs (mRNAs) has been described to date, but only the 120-, 140-, and 180- kDa isoforms are commonly expressed. NCAM1 plays an important role in the regulation of neurogenesis, neurite outgrowth, proliferation, and cell migration, however, its function in hematopoiesis, including NK cells, is poorly understood. NCAM1 signaling is mediated either by homophilic or heterophilic interactions with fibroblast growth factor receptor (FGFR), L1-CAM, N-cadherin and other components of the extracellular matrix. Upon activation, NCAM1 triggers a variety of signaling cascades including FYN–focal adhesion kinase (FAK), MAPK, and phosphatidylinositol 3-kinase (PI3K) pathways.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Neural cell adhesion molecule 1

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    5 Détails

  • Étape de développement la plus élevée:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte